Partnership combines world-renowned pharmaceutical leadership with an agile health-tech platform to make the ...
People aged 75 to 79, as well as people who turned 80 after 1 September 2024, are eligible for a vaccine to protect against respiratory syncytial virus (RSV). RSV affects the airways and lungs and can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback